Riskpilot← Back to searchSign inGet full accessNORDIC BIOTECH INCENTIVE ApS
APSIn liquidationCVR 26277779Strandvejen 125Activities of holding companies · NACE 6421Est. 2001— employees
Revenue 2024
DKK -243K
-282% vs 2023
EBITDA margin
100.0%
-282% vs 2023
Equity ratio
96.1%
Financial strength
Net profit 2024
DKK 4,9M
+13813% vs 2023
| Revenue | DKK -243K | -282% |
| EBITDA | DKK -243K | -282% |
| Net profit | DKK 4,9M | +13813% |
| Total assets | DKK 6,8M | +295% |
| Equity | DKK 6,6M | +289% |
| Employees | — | — |
Legal name
NORDIC BIOTECH INCENTIVE ApS
CVR number
26277779
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
28. september 2001
Share capital
DKK 300.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at være klasse B begrænset partner investor i Nordic Biotech K/S.
Address
Strandvejen 125
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | -12 | -16 | -20 | -21 | 51.133 | -43 | -29 | -17 | -15 | -18 | 133 | -243 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 7.928 | 12.500 | 86.146 | 24.179 | -21 | 51.133 | -43 | -29 | -17 | -15 | -18 | 133 | -243 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 7.928 | 12.500 | 86.146 | 24.179 | -21 | 51.133 | -43 | -29 | -17 | -15 | -18 | 133 | -243 |
| Net financials | -0 | 12.519 | 86.161 | 24.198 | -58.318 | -45.862 | -23.072 | 653 | -70 | -323 | -2.244 | -100 | 5.114 |
| Profit before tax | 7.928 | 12.507 | 86.145 | 24.178 | -58.339 | 5.271 | -23.115 | 624 | -87 | -338 | -2.262 | 33 | 4.871 |
| Tax | 2 | -0 | -0 | -0 | -0 | 15 | -0 | -0 | -0 | -0 | -0 | 68 | -0 |
| Net profit | 7.926 | 12.507 | 86.145 | 24.178 | -58.339 | 5.257 | -23.115 | 624 | -87 | -338 | -2.262 | -36 | 4.871 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 8.095 | 20.602 | 106.751 | 130.933 | 72.642 | 26.963 | 3.799 | 4.423 | 4.329 | 3.990 | 1.734 | 1.728 | 6.821 |
| Equity | 8.083 | 20.590 | 106.735 | 130.913 | 72.575 | 26.897 | 3.782 | 4.406 | 4.319 | 3.980 | 1.718 | 1.683 | 6.554 |
| Long-term debt | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 12 | 12 | 0 | 20 | 68 | 66 | 18 | 17 | 10 | 10 | 16 | 45 | 267 |
| Total debt | 12 | 12 | 16 | 20 | 68 | 66 | 18 | 17 | 10 | 10 | 16 | 45 | 267 |
EBITDA margin
-24305400.0%
This company
15.8%
Market median
-153831746% vs market
20122024
Equity ratio
96.1%
This company
38.2%
Market median
+152% vs market
20122024
Return on equity
74.3%
This company
18.4%
Market median
+304% vs market
20122024
Net profit margin
487103400.0%
This company
8.1%
Market median
+6013622122% vs market
20122024
Asset turnover
-0.04×
This company
1.12×
Market median
-104% vs market
20122024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LH Founder | Founder | 2001 | — | — |
TB Founder | Founder | 2001 | — | — |
JM Founder | Founder | 2001 | — | — |
JM Unofficial title | Unofficial title | 2026 | — | — |
WA Founder | Founder | 2001 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2003 | — | — | |
| Chairman | 2003 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KASTAN ApS | Company | 20.0% | 20.0% | 2012 |
C. HANSEN INVEST ApS | Company | 15.0% | 15.0% | 2006 |
| Individual | 10.0% | 10.0% | 2005 | |
CADENZA PARTNERS ApS | Company | 10.0% | 10.0% | 2005 |
| Individual | 5.0% | 5.0% | 2003 | |
| Individual | 5.0% | 5.0% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
C. HANSEN INVEST ApS
NORDIC BIOTECH INCENTIVE ApS Board members of NORDIC BIOTECH INCENTIVE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Helth Jensen | Founder | 0 companies |
| Tamas Bartfai | Founder | 0 companies |
| Jan Møller Mikkelsen | Founder | 0 companies |
| Jakob Mosegaard Larsen | Unofficial title | 0 companies |
| William A Scott | Founder | 0 companies |
| Christian Karsten Hansen | Board of Directors | 0 companies |
| Florian Schønharting | Chairman | 0 companies |